Workplace Cannabis Impairment: Detection, Laws & Employer Policies

Executive Summary

Workplace cannabis impairment has emerged as one of the most contentious issues in American labor law as 38 states have legalized medical or adult-use marijuana while employers struggle to maintain safety standards without reliable real-time impairment testing. Unlike alcohol, where breathalyzers measure current intoxication, THC metabolites remain detectable in urine for weeks after use, creating a legal and scientific quagmire for employers, employees, and courts. Recent data from the National Safety Council indicates workplace cannabis-related incidents increased 34% between 2019 and 2025, while simultaneously, wrongful termination lawsuits over off-duty cannabis use have tripled in states with employee protection statutes. The collision between state legalization laws, federal prohibition under the Controlled Substances Act (21 U.S.C. § 812), and workplace safety regulations has created a patchwork of conflicting standards affecting 160 million American workers. Employers in safety-sensitive industries face particular challenges: a 2024 Federal Motor Carrier Safety Administration rule mandates hair follicle testing for commercial drivers, while state courts in New Jersey and New York have ruled employers cannot terminate employees for lawful off-duty use. This hub provides the comprehensive legal, scientific, and practical framework employers, employees, and policymakers need to navigate this evolving landscape.

Why This Matters

The workplace cannabis impairment debate affects 160 million American workers, $2.1 trillion in annual payroll, and the fundamental balance between employee privacy rights and employer liability exposure. For employers, the stakes are measured in workers' compensation claims, OSHA citations, and negligent hiring lawsuits. A 2025 Liberty Mutual study found companies with safety-sensitive positions spent an average of $47,000 per cannabis-related workplace incident, including investigation costs, legal fees, and productivity losses. Manufacturing facilities, construction sites, and transportation companies face additional pressure from insurance carriers, who have increased premiums 12-18% for businesses in legalized states without robust drug-free workplace programs. For employees, cannabis impairment policies determine job security, medical treatment options, and privacy rights. Approximately 4.3 million Americans hold state-issued medical marijuana cards, according to 2025 data from Marijuana Policy Project. Many face impossible choices: use state-legal medicine for chronic pain, PTSD, or epilepsy and risk termination, or forgo treatment to maintain employment. The Americans with Disabilities Act (42 U.S.C. § 12101) does not require accommodation for medical marijuana use because cannabis remains federally illegal, leaving patients vulnerable. State governments confront revenue implications and public safety mandates. Colorado collected $423 million in marijuana tax revenue in 2025, funds earmarked for schools and infrastructure. Yet the state's Department of Labor reported 1,847 workplace injuries involving cannabis-positive drug tests that same year, creating political pressure to tighten workplace regulations that could reduce legal sales. Federal agencies face enforcement paradoxes. The Drug Enforcement Administration classifies cannabis as Schedule I, the most restrictive category, while the Department of Transportation struggles to implement testing protocols that distinguish impairment from residual metabolites. The Occupational Safety and Health Administration has issued no formal guidance on cannabis impairment, leaving employers to navigate conflicting state laws without federal clarity.

Background and History

The workplace cannabis impairment crisis emerged from the collision of 1980s drug testing mandates with 21st-century state legalization, creating legal conflicts that remain unresolved four decades later.

The Drug-Free Workplace Act Era (1988-1996)

The modern framework began with the Drug-Free Workplace Act of 1988 (41 U.S.C. § 8101), which required federal contractors and grantees to maintain drug-free workplaces. President Ronald Reagan's Executive Order 12564, issued in 1986, mandated drug testing for federal employees in safety-sensitive positions. These policies established the principle that employers could test for and prohibit any federally illegal substance, including cannabis. The Department of Transportation implemented comprehensive testing regulations in 1991 under 49 CFR Part 40, requiring pre-employment, random, post-accident, and reasonable suspicion testing for safety-sensitive transportation workers. The regulations set a 50 ng/mL cutoff for THC metabolites in urine, a threshold that detected use days or weeks prior, not current impairment. This standard became the de facto national benchmark, adopted by private employers across industries.

Medical Marijuana Collides With Employment Law (1996-2012)

California's Compassionate Use Act of 1996 (Proposition 215) legalized medical marijuana but included no employment protections. The California Supreme Court's 2008 decision in Ross v. RagingWire Telecommunications held that employers could terminate employees for medical marijuana use despite state legalization, because the federal Controlled Substances Act preempted state law and the Americans with Disabilities Act did not protect federally illegal drug use. This precedent established that state legalization alone provided no workplace protections. Montana became the first state to include explicit employment protections in its 2004 medical marijuana law, prohibiting discrimination against cardholders. However, the statute exempted safety-sensitive positions and allowed employers to prohibit impairment during work hours. Arizona's 2010 Medical Marijuana Act (A.R.S. § 36-2801) included stronger language, stating employers could not discriminate against qualified patients "unless the patient used, possessed or was impaired by marijuana on the premises of the place of employment or during the hours of employment." This created a new standard: employers could prohibit on-duty impairment but not off-duty use.

Adult-Use Legalization and the Impairment Testing Gap (2012-2020)

Colorado and Washington legalized adult-use cannabis in 2012, but both states explicitly preserved employer rights to maintain drug-free workplaces. Colorado's Amendment 64 stated nothing in the law "is intended to require an employer to permit or accommodate the use, consumption, possession, transfer, display, transportation, sale or growing of marijuana in the workplace." Washington's Initiative 502 contained identical language. The lack of reliable impairment testing became acute. A 2017 National Institute on Drug Abuse study found that THC blood levels peaked within 10 minutes of smoking but dropped below detection within 3-4 hours, while urine tests remained positive for 30 days in regular users. Oral fluid testing showed promise for detecting recent use, but the Substance Abuse and Mental Health Services Administration did not approve oral fluid testing guidelines until 2020. Colorado attempted to establish a legal THC blood limit of 5 ng/mL for driving under its 2013 law (C.R.S. § 42-4-1301.1), but studies by AAA and the National Highway Traffic Safety Administration found no correlation between THC blood levels and impairment, unlike alcohol's linear relationship. This scientific gap left employers without objective impairment standards.

Employee Protection Statutes and Judicial Expansion (2020-Present)

New Jersey's 2021 Cannabis Regulatory, Enforcement Assistance, and Marketplace Modernization Act (N.J.S.A. 24:6I-1) marked a turning point, explicitly prohibiting employers from taking adverse action against employees for off-duty cannabis use and requiring employers to demonstrate actual impairment, not merely positive drug tests. The law defined impairment as "being under the influence of cannabis such that it inhibits or diminishes the ability of a person to perform work-related duties." New York's Marijuana Regulation and Taxation Act of 2021 (N.Y. Cannabis Law § 201) went further, prohibiting discrimination based on cannabis use and stating that testing positive for cannabis metabolites alone could not establish impairment. The law required employers to show "articulable symptoms of impairment that decrease or lessen the employee's performance of the duties or tasks of the employee's job position." Montana's Supreme Court issued a landmark decision in 2022 in Fossen v. Blue Cross Blue Shield, holding that the state's medical marijuana law required reasonable accommodation for off-duty use unless the employer could demonstrate actual impairment or undue hardship. This extended disability accommodation principles to cannabis, a novel legal theory. By 2025, 19 states had enacted some form of employment protection for cannabis users, creating a complex patchwork. Connecticut, Rhode Island, Illinois, Nevada, and Pennsylvania prohibited discrimination against medical marijuana patients. California, Massachusetts, and Michigan courts issued rulings limiting employer drug testing authority. The legal landscape had shifted from blanket employer authority to a nuanced, state-specific analysis of impairment versus use.

Key Players

Drug Enforcement Administration

The DEA maintains cannabis as a Schedule I controlled substance under 21 U.S.C. § 812, the classification that underpins federal prohibition and employer drug testing authority. In August 2024, the DEA proposed rescheduling cannabis to Schedule III following a Department of Health and Human Services recommendation, but the rule remained under review as of May 2026. Rescheduling would not eliminate federal prohibition or alter most workplace testing programs, but it could affect federal contractor obligations and create new legal arguments for employee protections.

Occupational Safety and Health Administration

OSHA has issued no formal guidance on cannabis impairment, but the agency's General Duty Clause (29 U.S.C. § 654) requires employers to provide workplaces "free from recognized hazards." OSHA citations following workplace accidents frequently reference positive drug tests as evidence of safety violations, even when impairment cannot be established. In 2023, OSHA proposed a rule requiring employers to conduct root cause analysis of injuries rather than relying solely on drug testing, but the rule faced industry opposition and remained unpublished.

Department of Transportation

The DOT regulates 13 million safety-sensitive transportation workers under 49 CFR Part 40. In March 2024, the Federal Motor Carrier Safety Administration published a final rule adding hair follicle testing as an alternative to urine testing, detecting cannabis use up to 90 days prior. The rule faced immediate legal challenges from the Owner-Operator Independent Drivers Association, which argued hair testing was not scientifically validated for impairment. As of May 2026, implementation remained stayed pending litigation.

Quest Diagnostics

Quest Diagnostics, the nation's largest drug testing laboratory, processes 10 million workplace drug tests annually. The company's Drug Testing Index reported that cannabis positivity rates reached 4.5% in 2025, the highest level in 20 years. Quest has developed oral fluid testing protocols and promoted alternative matrices, but urine testing remains the industry standard due to DOT requirements and established cutoff levels.

National Organization for the Reform of Marijuana Laws

NORML has advocated for employee protections since the 1990s, publishing model legislation and supporting litigation challenging employer drug testing. The organization's Workplace Fairness Project, launched in 2021, provides legal resources to employees facing termination for off-duty use. NORML's deputy director, Paul Armentano, has testified before state legislatures in New Jersey, New York, Connecticut, and Nevada in support of employee protection statutes.

Society for Human Resource Management

SHRM represents 300,000 HR professionals navigating cannabis policies. The organization has published guidance recommending employers focus on impairment rather than use, implement supervisor training on behavioral observation, and consult legal counsel before implementing testing programs in states with employee protections. SHRM's 2025 survey found 67% of employers had revised drug testing policies since 2020 due to state legalization laws.

National Safety Council

The NSC's Impairment Detection Program promotes behavioral observation training as an alternative to drug testing. The organization's 2025 report, "Cannabis and the Workplace," found that supervisor training reduced workplace incidents by 23% compared to drug testing alone. The NSC advocates for performance-based impairment assessment rather than metabolite detection.

Legal and Regulatory Framework

Workplace cannabis impairment law operates at the intersection of federal drug prohibition, state legalization statutes, employment discrimination law, and occupational safety regulations, creating conflicts that courts resolve on a case-by-case basis. The Controlled Substances Act (21 U.S.C. § 812) classifies cannabis as Schedule I, making possession and use federal crimes. This classification provides the legal foundation for employer drug testing and termination, as employers can prohibit federally illegal conduct regardless of state law. The Supremacy Clause (U.S. Const. art. VI, cl. 2) establishes that federal law preempts conflicting state law, a principle the Supreme Court affirmed in Gonzales v. Raich, 545 U.S. 1 (2005). The Americans with Disabilities Act (42 U.S.C. § 12101) prohibits employment discrimination based on disability but explicitly excludes protections for current illegal drug use. Section 12114(a) states the Act does not protect "an individual who is currently engaging in the illegal use of drugs, when the covered entity acts on the basis of such use." Because cannabis remains federally illegal, courts have consistently held that the ADA does not require accommodation for medical marijuana use, as established in James v. City of Costa Mesa, 700 F.3d 394 (9th Cir. 2012). State medical marijuana laws create the first layer of complexity. As of May 2026, 38 states have legalized medical cannabis, but only 19 include employment protections. These protections range from narrow prohibitions on discrimination (Arizona, Arkansas, Connecticut) to broad requirements for reasonable accommodation (Montana, New Jersey, New York). Most statutes include exceptions for safety-sensitive positions, federal contractors, and on-duty impairment. State adult-use legalization laws generally preserve employer authority. Colorado's Amendment 64, Washington's Initiative 502, Oregon's Measure 91, and Alaska's Ballot Measure 2 all explicitly state that employers may maintain drug-free workplaces and prohibit cannabis use. However, recent statutes in New Jersey, New York, Connecticut, and Rhode Island limit employer authority by requiring demonstration of actual impairment rather than positive drug tests. State disability discrimination laws provide an alternative legal theory. In Barbuto v. Advantage Sales and Marketing, 477 Mass. 456 (2017), the Massachusetts Supreme Judicial Court held that the state's disability discrimination law required employers to engage in the interactive process and consider accommodation for medical marijuana use, even though the ADA provided no protection. This created a state-law accommodation requirement independent of federal law. Workers' compensation statutes in 16 states include rebuttable presumptions that workplace injuries involving positive drug tests resulted from intoxication, shifting the burden to employees to prove otherwise. Florida Statutes § 440.09(3) reduces workers' compensation benefits by 50% if the employee was impaired by drugs at the time of injury. These provisions create powerful incentives for employers to conduct post-accident testing. The Drug-Free Workplace Act (41 U.S.C. § 8101) requires federal contractors to maintain drug-free workplace policies, including employee notification of drug convictions and good-faith efforts to maintain drug-free workplaces. While the Act does not mandate drug testing, federal contractors generally implement testing programs to demonstrate compliance. Approximately 1.2 million employers hold federal contracts subject to the Act. Department of Transportation regulations (49 CFR Part 40) establish mandatory testing protocols for 13 million safety-sensitive transportation workers, including truck drivers, pilots, railroad engineers, and transit operators. The regulations require testing at 50 ng/mL for THC-COOH in urine, with confirmatory testing at 15 ng/mL. DOT regulations preempt state laws that would prohibit testing or protect employees who test positive.

State-by-State Breakdown

Employment protections for cannabis users vary dramatically by state, creating compliance challenges for multi-state employers and uncertainty for mobile workers.

Arizona

The Arizona Medical Marijuana Act (A.R.S. § 36-2801) prohibits discrimination against medical marijuana cardholders unless the patient was impaired during work hours or possessed cannabis on the employer's premises. The Arizona Supreme Court's 2015 decision in Whitmire v. Wal-Mart Stores held that employers must accommodate off-duty medical use unless they can demonstrate undue hardship. Possession limits: 2.5 ounces every 14 days for medical patients. Adult-use legalization (Proposition 207, effective 2021) allows 1 ounce possession but includes no employment protections beyond medical law.

California

California's Compassionate Use Act (Proposition 215) and Adult Use of Marijuana Act (Proposition 64) include no employment protections. The California Supreme Court's decision in Ross v. RagingWire Telecommunications, 42 Cal. 4th 920 (2008), held employers may terminate employees for off-duty medical marijuana use. However, Assembly Bill 2188, effective January 2024, prohibits discrimination based on off-duty cannabis use and prohibits employers from using drug tests that detect non-psychoactive cannabis metabolites. Employers may still test for THC (the psychoactive component) using blood or oral fluid tests. Possession limits: 8 ounces for medical patients, 1 ounce for adult use.

Connecticut

Connecticut's Palliative Use of Marijuana Act (Conn. Gen. Stat. § 21a-408) prohibits employers from refusing to hire or discharging employees solely based on medical marijuana patient status. Public Act 21-1, effective July 2021, extended protections to adult-use consumers, prohibiting adverse employment actions based on off-duty cannabis use. Employers may prohibit on-duty use and impairment. Possession limits: 2.5 ounces per month for medical patients, 1.5 ounces for adult use.

Illinois

The Illinois Cannabis Regulation and Tax Act (410 ILCS 705) prohibits employers from disciplining employees for off-duty cannabis use but allows employers to maintain zero-tolerance policies for safety-sensitive positions and to prohibit on-duty impairment. The Act does not require employers to accommodate on-site use or permit employees to work while impaired. Possession limits: 2.5 ounces every 14 days for medical patients, 30 grams for adult use (15 grams for non-residents).

Montana

Montana's medical marijuana law (Mont. Code Ann. § 50-46-101) prohibits discrimination against cardholders. The Montana Supreme Court's 2022 decision in Fossen v. Blue Cross Blue Shield held that employers must reasonably accommodate off-duty medical use unless they can demonstrate actual impairment or undue hardship. Adult-use legalization (Initiative 190, effective 2021) includes no employment protections. Possession limits: 5 ounces for medical patients, 1 ounce for adult use.

Nevada

Nevada Revised Statutes § 678.442, effective January 2020, prohibits employers from refusing to hire applicants based on positive pre-employment marijuana tests, with exceptions for safety-sensitive positions, federal contractors, and positions requiring federal background checks. The law does not protect current employees from termination for positive tests. Possession limits: 2.5 ounces for medical patients, 1 ounce for adult use.

New Jersey

New Jersey's Cannabis Regulatory, Enforcement Assistance, and Marketplace Modernization Act (N.J.S.A. 24:6I-1) prohibits employers from taking adverse action against employees for off-duty cannabis use. Employers must demonstrate actual impairment through "physical, behavioral, or performance indicators" and may not rely solely on positive drug tests. The law requires employers to conduct observational impairment assessments. Possession limits: 3 ounces for medical patients, 1 ounce for adult use.

New York

New York's Marijuana Regulation and Taxation Act (N.Y. Cannabis Law § 201) prohibits discrimination based on cannabis use and states that testing positive for cannabis metabolites alone cannot establish impairment. Employers must demonstrate "articulable symptoms of impairment" that affect job performance. The law allows employers to prohibit on-duty use and to take action when employees are actually impaired. Possession limits: 60-day supply for medical patients (specific amount determined by practitioner), 3 ounces for adult use.

Oklahoma

Oklahoma's medical marijuana law (Okla. Stat. tit. 63, § 420) includes no explicit employment protections, but the statute states that employers may not discriminate against medical marijuana license holders "unless failing to do so would cause the employer to lose a monetary or licensing-related benefit under federal law." This creates a narrow exception for federal contractors but suggests broader protections for other employers. Courts have not yet interpreted this provision. Possession limits: 3 ounces for medical patients (8 ounces at home). No adult-use program.

Pennsylvania

Pennsylvania's Medical Marijuana Act (35 P.S. § 10231.2103) prohibits discrimination against medical marijuana patients unless the patient used, possessed, or was impaired at work or the patient's use would create a safety risk. The statute does not require accommodation for on-site use. No adult-use program. Possession limits: 30-day supply for medical patients (specific amount determined by practitioner).

Rhode Island

Rhode Island's Edward O. Hawkins and Thomas C. Slater Medical Marijuana Act (R.I. Gen. Laws § 21-28.6-7) prohibits employers from refusing to hire or discharging employees based solely on medical marijuana patient status. The statute allows employers to prohibit on-duty impairment. Adult-use legalization (Rhode Island Cannabis Act, effective 2022) extends protections to adult-use consumers. Possession limits: 2.5 ounces for medical patients, 1 ounce for adult use.

Market and Business Implications

Workplace cannabis policies directly impact labor costs, insurance premiums, legal liability, and talent acquisition in the $33.6 billion U.S. cannabis industry and the broader economy. Multi-state operators face compliance complexity across 38 state programs with conflicting employment standards. Curaleaf, Trulieve, Green Thumb Industries, and Cresco Labs operate in 15-20 states each, requiring separate drug testing policies, supervisor training programs, and legal review for each jurisdiction. Compliance costs average $125,000 annually per state for large operators, according to a 2025 analysis by Viridian Capital Advisors. Insurance carriers have responded to legalization by adjusting workers' compensation and general liability premiums. A 2024 study by the National Council on Compensation Insurance found that employers in legalized states without robust drug-free workplace programs experienced 8-12% higher workers' compensation costs compared to prohibition states. Carriers now require detailed drug testing policies, supervisor training documentation, and post-accident testing protocols as underwriting criteria. Talent acquisition has shifted in tight labor markets. A 2025 survey by the Society for Human Resource Management found that 38% of employers in legalized states had eliminated pre-employment marijuana testing for non-safety-sensitive positions to expand applicant pools. Amazon announced in 2021 it would no longer test most positions for cannabis, a policy other major employers including Walmart and Target adopted by 2024. This created competitive pressure on smaller employers to liberalize policies or face staffing shortages. Safety-sensitive industries face acute challenges. The construction industry, which employs 11 million workers, reported 1,069 fatal workplace injuries in 2024, with cannabis detected in 18% of post-accident drug tests according to the Bureau of Labor Statistics. The Associated General Contractors of America has advocated for federal preemption of state employment protection laws for construction workers, but no legislation has advanced. The trucking industry confronts a driver shortage of 78,000 positions as of 2025 while maintaining DOT drug testing requirements. The American Trucking Associations has opposed oral fluid testing and hair follicle testing expansions, arguing they detect use too far removed from work hours. The industry faces a paradox: strict testing reduces the driver pool, but relaxed standards increase liability exposure and insurance costs. Technology companies have largely eliminated cannabis testing. Google, Apple, Microsoft, and Meta do not test for cannabis except for positions requiring federal security clearances. The tech industry's concentration in California, Washington, and Colorado—early legalization states—drove policy liberalization. A 2024 analysis by Revelio Labs found that tech companies that eliminated cannabis testing experienced 14% faster hiring velocity compared to companies maintaining testing. Federal contractors remain bound by Drug-Free Workplace Act requirements, creating a two-tier labor market. Lockheed Martin, Boeing, Raytheon, and other defense contractors maintain zero-tolerance policies, while commercial competitors can liberalize policies. This affects recruitment: a 2025 survey by ClearanceJobs found that 23% of potential applicants for cleared positions reported avoiding federal contractor jobs due to cannabis policies.

What Experts Say

Scientific, legal, and industry experts emphasize the gap between drug testing technology and actual impairment assessment as the central challenge in workplace cannabis policy. According to research published by the National Institute on Drug Abuse in 2024, THC blood levels correlate poorly with impairment because tolerance varies dramatically among users. Regular consumers may show high THC levels with minimal impairment, while occasional users may be significantly impaired at lower levels. The study concluded that behavioral observation and performance testing provide more reliable impairment indicators than biological testing. Paul Armentano, deputy director of the National Organization for the Reform of Marijuana Laws, has stated in legislative testimony that urine testing for cannabis metabolites is "analogous to firing an employee on Monday for drinking beer on Saturday." He advocates for performance-based impairment assessment and limiting testing to post-accident and reasonable suspicion scenarios. The American Civil Liberties Union has challenged workplace drug testing programs as violations of privacy rights, particularly in states with constitutional privacy protections. ACLU staff attorney Jennesa Calvo-Friedman stated in a 2024 brief that "employers have legitimate interests in workplace safety, but those interests do not extend to monitoring employees' off-duty, lawful conduct that has no impact on job performance." Employers' counsel take a different view. Management-side employment attorney Michael Kun of Epstein Becker Green has advised clients that even in states with employee protections, employers retain authority to prohibit on-duty impairment and to conduct testing when they observe specific, articulable symptoms. He recommends detailed documentation of behavioral observations and supervisor training on impairment recognition. The National Safety Council's Impairment Detection Program emphasizes supervisor training over drug testing. According to the organization's 2025 guidance, trained supervisors can identify impairment through observation of physical symptoms (bloodshot eyes, odor, unsteady gait), behavioral changes (confusion, slowed reaction time, poor judgment), and performance deficits (increased errors, accidents, absenteeism). The NSC recommends a two-supervisor observation protocol before removing employees from safety-sensitive positions. Toxicologists have developed alternative testing methods focused on recent use. Oral fluid testing detects THC for 12-24 hours after use, providing a narrower detection window than urine's 30-day window. However, the Substance Abuse and Mental Health Services Administration did not publish final oral fluid testing guidelines until 2020, and many employers have not adopted the methodology due to higher costs and lack of DOT approval for safety-sensitive positions. Researchers at the University of California San Diego published a 2023 study in JAMA Psychiatry finding that cannabis users showed impairment on driving simulator tests for 3-4 hours after smoking, but impairment was not detectable after 6 hours. The study suggested that time-based restrictions (prohibiting use within 8 hours of work) might provide more accurate impairment prevention than drug testing.

What's Next

The workplace cannabis impairment landscape will evolve through federal rescheduling decisions, state legislative activity, judicial precedents, and technology development over the next 24-36 months. The DEA's rescheduling decision, expected by late 2026, will determine whether cannabis moves from Schedule I to Schedule III under the Controlled Substances Act. Rescheduling would not legalize cannabis or eliminate federal prohibition, but it could affect Drug-Free Workplace Act interpretations and create new legal arguments for employee protections. Federal contractors and DOT-regulated employers would likely remain subject to testing requirements regardless of scheduling. State legislatures in Ohio, Missouri, Maryland, and Minnesota are considering employment protection statutes for 2026-2027 sessions. Ohio's proposed legislation would prohibit discrimination against medical marijuana patients and require employers to demonstrate actual impairment. Missouri's bill would extend protections to adult-use consumers. These states represent 28 million workers, and passage would significantly expand the employee protection landscape. The U.S. Court of Appeals for the Third Circuit is reviewing a case, Cotto v. Ardagh Glass Packing, involving New Jersey's employment protection statute and federal preemption under the Drug-Free Workplace Act. The case, argued in March 2026, will determine whether state laws protecting cannabis users conflict with federal contractor obligations. A ruling favoring federal preemption could invalidate employment protections for millions of workers at companies holding federal contracts. Technology development focuses on point-of-collection impairment testing. Hound Labs, SannTek Labs, and Cannabix Technologies are developing breathalyzers that detect THC in breath for 2-3 hours after use, approximating the impairment window. However, these devices have not received FDA approval or DOT authorization as of May 2026. If approved, breath testing could provide the objective impairment standard employers and employees both seek. The Occupational Safety and Health Administration's proposed rule on workplace injury investigation, which would require root cause analysis beyond drug testing, faces a comment period closing in August 2026. If finalized, the rule would reduce employer reliance on post-accident drug testing and shift focus to systemic safety improvements. Industry groups including the National Association of Manufacturers have opposed the rule as burdensome. Federal legislation remains stalled. The Marijuana Opportunity Reinvestment and Expungement (MORE) Act, which would deschedule cannabis and provide employment protections, passed the House in 2022 but died in the Senate. The Cannabis Administration and Opportunity Act, introduced in 2023, includes employment provisions but has not advanced. Comprehensive federal reform appears unlikely before 2028 absent significant political shifts. Employer practices will continue evolving toward impairment-based policies. The Society for Human Resource Management projects that by 2028, 60% of employers will have eliminated pre-employment cannabis testing for non-safety-sensitive positions, and 40% will have adopted behavioral observation protocols as primary impairment detection methods. This shift reflects labor market pressures, legal risks in states with employee protections, and recognition that metabolite testing does not measure impairment.

Further Reading

• Drug Enforcement Administration, Docket No. DEA-407, "Schedules of Controlled substances: Rescheduling of Marijuana" (Proposed Rule, August 2024) — https://www.federalregister.gov/documents/2024/08/30/2024-19565/schedules-of-controlled-substances-rescheduling-of-marijuana
• National Institute on Drug Abuse, "Cannabis (Marijuana) Research Report: What are marijuana's effects on general physical health?" (Updated 2024) — https://nida.nih.gov/publications/research-reports/marijuana/what-are-marijuanas-effects-general-physical-health
• Society for Human Resource Management, "Managing Marijuana in the Workplace" (2025 Edition) — https://www.shrm.org/resourcesandtools/legal-and-compliance/state-and-local-updates/pages/managing-marijuana-in-the-workplace.aspx
• National Safety Council, "Cannabis and the Workplace: Addressing Impairment" (2025) — https://www.nsc.org/workplace/safety-topics/drugs-at-work/cannabis
• U.S. Department of Transportation, Federal Motor Carrier Safety Administration, 49 CFR Part 40, "Procedures for Transportation Workplace Drug and Alcohol Testing Programs" — https://www.ecfr.gov/current/title-49/subtitle-A/part-40
• Quest Diagnostics, "Drug Testing Index: Analysis of Workforce Drug Test Results" (2025) — https://www.questdiagnostics.com/business-solutions/employer-solutions/drug-testing/drug-testing-index
• American Civil Liberties Union, "Drug Testing: A Bad Investment" (Updated 2024) — https://www.aclu.org/other/drug-testing-bad-investment
• New Jersey Cannabis Regulatory Commission, "Workplace Impairment Recognition Training" — https://www.nj.gov/cannabis/businesses/employer-information/
• Barbuto v. Advantage Sales and Marketing, 477 Mass. 456 (2017) — Full text available at https://www.mass.gov/supreme-judicial-court-opinions
• Ross v. RagingWire Telecommunications, 42 Cal. 4th 920 (2008) — Full text available at https://www.courts.ca.gov/opinions.htm